Sbornik lekarsky · 1995
[The effect of polyene phosphatidylcholine administration on lipid metabolism and glucose tolerance in patients with hyperlipoproteinemia IIB].
Клиническое исследованиеАннотация на английскомСтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zeman M, Zák A, Stolba P
Аннотация
BACKGROUND: Up to now, clinical and experimental studies have brought only inconsistent data about the effectiveness of polyene phosphatidylcholine (PPC) in treatment of dyslipidemia. The aim of this randomized, double blind study was to verify the effects of the polyene phosphatidylcholine preparation Lipostabil forte R (Rhone-Poulenc-Röhrer, Köln, FRG), given orally in a daily dose 2.7 g for three months to patients with hyperlipoproteinemia type IIB and hypoalfacholesterolemia both on the plasma lipids, lipoproteins, apolipoproteins and the parameters of glucose tolerance.
METHODS AND RESULTS: Administration of PPC to 30 patients with hyperlipoproteinemia type IIB and hypoalfacholesterolemia led to a significant rise of HDL-cholesterol, HDL3-cholesterol and plasma apolipoprotein A-I concentrations in comparison with the group treated with placebo. At the same time, plasma apolipoprotein B concentration slightly increased. Blood glucose, immunoreactive insulin and non-esterified fatty acid concentrations during the oral glucose tolerance test didn't change significantly after PPC administration.
CONCLUSIONS: It seems PPC could be the appropriate supplement to the treatment of patients with decreased concentrations of HDL-cholesterol and plasma apolipoprotein A-I.
METHODS AND RESULTS: Administration of PPC to 30 patients with hyperlipoproteinemia type IIB and hypoalfacholesterolemia led to a significant rise of HDL-cholesterol, HDL3-cholesterol and plasma apolipoprotein A-I concentrations in comparison with the group treated with placebo. At the same time, plasma apolipoprotein B concentration slightly increased. Blood glucose, immunoreactive insulin and non-esterified fatty acid concentrations during the oral glucose tolerance test didn't change significantly after PPC administration.
CONCLUSIONS: It seems PPC could be the appropriate supplement to the treatment of patients with decreased concentrations of HDL-cholesterol and plasma apolipoprotein A-I.